Associated Papers
Inotuzumab therapy resulted in molecular remission of relapsed/resistant B-cell acute lymphoblastic leukemia with BCR::ABL1 Lys404Glu mutation.
Lewandowski K et al.
Annals of Hematology, 2025
Treatment-Emergent Resistance to Asciminib in Chronic Myeloid Leukemia Patients Due to Myristoyl-Binding Pocket-Mutant of BCR::ABL1/A337V Can Be Effectively Overcome with Dasatinib Treatment.
Batar P et al.
Current Oncology (toronto, Ont.), 2025
Impact of BCR::ABL1 single nucleotide variants on asciminib efficacy.
Innes AJ et al.
Leukemia, 2024
Overcoming Secondary Mutations of Type II Kinase Inhibitors.
Wang X et al.
Journal of Medicinal Chemistry, 2024
Characterization of Asciminib-Resistant Philadelphia Chromosome-Positive Cells.
Okabe S et al.
World Journal of Oncology, 2024
In vitro evidence of synergistic efficacy with asciminib combined with reduced dose of ATP-binding pocket tyrosine kinase inhibitors according to the ABL1 kinase domain mutation profile.
Han HJ et al.
Leukemia, 2024
The Dawn of Allosteric BCR-ABL1 Drugs: From a Phenotypic Screening Hit to an Approved Drug.
Teng M et al.
Journal of Medicinal Chemistry, 2022
Development of asciminib, a novel allosteric inhibitor of BCR-ABL1.
Réa D et al.
Critical Reviews in Oncology/hematology, 2022
Genomic Mechanisms Influencing Outcome in Chronic Myeloid Leukemia.
Fernandes A et al.
Cancers, 2022
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants.
Eide CA et al.
Cancer Cell, 2019
BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia.
Antelope O et al.
Experimental Hematology, 2019
Identification and characterization of activating ABL1 1b kinase mutations: impact on sensitivity to ATP-competitive and allosteric ABL1 inhibitors.
Lee BJ et al.
Leukemia, 2017
Select a paper to view details